Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core

J Med Chem. 2017 Feb 23;60(4):1611-1616. doi: 10.1021/acs.jmedchem.6b01706. Epub 2017 Feb 3.

Abstract

A duplexed, functional multiaddition high throughput screen and subsequent optimization effort identified the first orally bioavailable and CNS penetrant glucagon-like peptide-1 receptor (GLP-1R) noncompetitive antagonist. Antagonist 5d not only blocked exendin-4-stimulated insulin release in islets but also lowered insulin levels while increasing blood glucose in vivo.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Blood Glucose / analysis
  • Blood Glucose / metabolism
  • Cells, Cultured
  • Central Nervous System / drug effects
  • Central Nervous System / metabolism
  • Glucagon-Like Peptide-1 Receptor / antagonists & inhibitors*
  • Glucagon-Like Peptide-1 Receptor / metabolism
  • Halogenation
  • Humans
  • Insulin / blood
  • Insulin / metabolism
  • Islets of Langerhans / drug effects
  • Islets of Langerhans / metabolism
  • Male
  • Pyrimidines / administration & dosage
  • Pyrimidines / chemistry*
  • Pyrimidines / pharmacokinetics
  • Pyrimidines / pharmacology*
  • Rats, Sprague-Dawley

Substances

  • Blood Glucose
  • Glucagon-Like Peptide-1 Receptor
  • Insulin
  • Pyrimidines